Covax to purchase 40M doses of Pfizer, BioNTech COVID-19 vaccine

By The Science Advisory Board staff writers

January 25, 2021 -- The Covax global vaccine initiative has reached a deal with Pfizer and BioNTech for 40 million doses of the Pfizer-BioNTech COVID-19 vaccine.

The Covax initiative was established by leading public health agencies, including the World Health Organization, to provide governments with early access to a large portfolio of COVID-19 vaccines. The new advance purchase agreement secures 40 million doses to be delivered throughout 2021.

The first doses are expected to be delivered in the first quarter of the year, and Pfizer and BioNTech will provide the vaccine to 92 low- and middle-income countries for not-for-profit pricing.

Terms of the agreement were not disclosed. The delivery is subject to supply agreements under the Covax Facility structure.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here